Tocilizumab improves disease activity regardless of anti-cyclic citrullinated peptide status in rheumatoid arthritis

Primary tabs

SCIENCE
Tocilizumab improves disease activity regardless of anti-cyclic citrullinated peptide status in rheumatoid arthritis
Key Take-Away: 

Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody used for the treatment of severe to moderate rheumatoid arthritis. Tocilizumab (TCZ) can improve the patient and physician measures of disease activity and it remains unaffected by the serological status of rheumatoid arthritis (RA) patient.

Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody used for the treatment of severe to moderate rheumatoid arthritis.

ABSTRACT: 
Background: 

Tocilizumab is a humanized anti-IL-6 receptor monoclonal antibody used for the treatment of severe to moderate rheumatoid arthritis. Autoantibodies can be useful in predicting response to specific treatments in RA.

The presented study by Cappelli L C and colleagues aimed to evaluate the initial response to TCZ by the change in physician and patient-reported outcomes and laboratory parameters in a real-world cohort of patients with RA. The data was analyzed using the autoantibody status to determine whether patients with seronegative RA had improved response to TCZ as compared to their seropositive counterparts.

Methods: 

Data from the CORRONA RA registry was analyzed. Patients on TCZ and having data from a follow-up visit 4–8 months after initiation, as well as having information on serological status were included in the study.

Serological status was determined by the presence of anti-cyclic citrullinated peptide (CCP) antibodies. Changes in disease activity measures from baseline to follow-up visit were evaluated.

Results: 

Both CCP-negative and -positive groups had statistically significant improvement in physician-reported measurements (physician rating of disease activity and joint counts), patient-reported measures (disease activity, pain, and fatigue), and acute phase reactants after 4–8 months of treatment with TCZ.

The magnitude of improvement, however did not differ significantly by the CCP status.

Conclusion: 

Tocilizumab showed a significant improvement in all patient- and physician-reported measures of disease activity evaluated in this cohort of patient with RA. The response to TCZ did not differ by the CCP status.

 

Source:

Seminars in Arthritis and Rheumatism

Link to the source:

http://www.semarthritisrheumatism.com/article/S0049-0172(16)30370-5/fulltext?rss=yes

The original title of the article:

Tocilizumab treatment leads to improvement in disease activity regardless of CCP status in rheumatoid arthritis

Authors:

Laura C. Cappelli et al.

Log in or register to post comments